Olof Eriksson receives SEK 1,3 million for PET project


Olof Eriksson, researcher in translational imaging, is awarded a Project Grant of SEK 1,303,000 from Diabetes Wellness Sweden for his project GPR44 as a PET marker for measuring beta cell mass in human.

Olof Eriksson, researcher in translational imaging, the Faculty of Pharmacy
Olof Eriksson, researcher in translational imaging, the Faculty of Pharmacy

Olof Eriksson, Associate Senior Lecturer at Uppsala University's Department of Medicinal Chemistry, will use the grant to develop and validate a new radioactive contrast agent for PET, which will enable imaging of the insulin-producing cells in the pancreas.

“Our long-term goal is to be able to measure the number of surviving insulin-producing cells in the pancreas with a short PET examination. We can then quickly evaluate various treatments aimed to protect or expand the insulin-producing cells. We could also understand how the amount of insulin-producing cells changes during the development of different types of diabetes, states Olof Eriksson.

The Diabetes Wellness Project Grant is a research grant awarded to research projects related to both type 1 and type 2 diabetes.



  • Uppsala University’s Uppsala University’s Preclinical PET-MRI platform bridge the gap between basic research in medicinal chemistry and clinical application of molecular imaging.
  • The platform work in close collaboration with collaboration with the Uppsala University Hospital PET centre.
  • The platform is part of a pilot initiative to develop a national resource for PET-MRI within SciLifeLab.


Contact Olof ErikssonOlof Eriksson, Associate Senior Lecturer
Department of Medicinal Chemistry
Email  olof.eriksson@ilk.uu.se

text: Magnus Alsne, photo: Mikael Wallerstedt

Research news

Last modified: 2021-05-31